In the United States, data from the National Diabetes Statistics Report (2024) reveal that 304,000 young people under the age of 20 are living with T1DM, highlighting the need for complementary therapies to insulin therapy, which often fails to control microvascular complications and glycemic variation [5]. Here, INS is linked to diabetes mellitus.